Back to results
US 2025/0026833 A1Published application
A bispecific anti-pd-l1/vegf antibody and uses thereof
AssigneeWuxi Biologics Ireland Limited
InventorsYi QIN, Zhuozhi WANG, Yunying CHEN, Jing LI, Jijie GU
Life of this patent
Estimating the term…
Abstract
The present disclosure provides bispecific anti-VEGF×PD-L1 antibody or antigen-binding portion thereof, methods of producing the bispecific antibody or antigen-binding portion thereof, methods of treating diseases or conditions using the bispecific antibody or antigen-binding portion thereof.
Claims21
1-26. (canceled)
A bispecific antibody or antigen-binding portion thereof, comprising a PD-L1 antigen-binding moiety associated with a VEGF antigen-binding moiety, wherein:
- the PD-L1 antigen-binding moiety comprises:
- a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 3, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- and
- the VEGF antigen-binding moiety comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 9, a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 10, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 11, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 12.
14 more elements
Dependencies are inferred from the claim text.